Atara Biotherapeutics snares $52 mln in Series B funds
Atara Biotherapeutics has raised $52 million in Series B financing. Investors in this round include Alexandria Venture Investments, Amgen Ventures, The Baupost Group, Celgene Corp., DAG Ventures, Domain Associates, EcoR1 Capital and Kleiner Perkins Caufield & Byers. Headquartered in Brisbane, Calif., Atara Biotherapeutics is focused on treating patients with cancer, kidney disease and other illnesses.
10 January 2014•2 mins read
